NCT04301778 2026-03-13
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
Clinical Trials
40 trialsNCT04705818 2026-03-06
CAIRE
Institut Bergonié
Phase 2 Completed
NCT04945720 2026-02-25
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03777813 2025-11-18
ARION
UNICANCER
Phase 2 Completed
NCT03638141 2025-08-17
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03212469 2025-05-08
ABIMMUNE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT05924880 2025-04-22
TopDouble
AstraZeneca
Phase 3 Completed
NCT03435107 2024-10-15
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Asan Medical Center
Phase 2 Completed
NCT02754856 2024-10-09
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04156087 2024-09-19
MIMIPAC
University Hospital, Gasthuisberg
Phase 2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03751761 2024-02-28
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Asan Medical Center
Phase 1/2 Completed
NCT04568200 2024-01-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT02870920 2023-12-08
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03206073 2023-10-24
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03611556 2023-10-03
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
MedImmune LLC
Phase 1/2 Completed
NCT02639065 2023-09-25
A Study of Durvalumab (MEDI4736) in Esophageal Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03428126 2023-06-15
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03473574 2023-06-15
IMMUCHEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT02821754 2023-03-28
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04124991 2023-03-16
SOLID
Seoul National University Hospital
Phase 1/2 Completed
NCT03202758 2023-02-10
MEDITREME
Centre Georges Francois Leclerc
Phase 1/2 Completed
NCT02963831 2022-12-22
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01975831 2022-10-12
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT03122509 2022-07-06
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03101475 2022-05-31
ILOC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03102047 2022-04-20
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
NSABP Foundation Inc
Phase 2 Completed
NCT02777710 2021-09-05
MEDIPLEX
Centre Leon Berard
Phase 1 Completed
NCT02227667 2021-06-18
Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02311361 2021-04-20
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02811497 2021-04-01
METADUR
University Health Network, Toronto
Phase 2 Completed
NCT01938612 2021-03-12
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02572687 2021-01-20
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Eli Lilly and Company
Phase 1 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT03005002 2019-12-26
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
City of Hope Medical Center
Phase 1 Completed
NCT02586987 2019-11-18
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02734160 2019-08-05
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02403271 2019-01-03
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Pharmacyclics LLC.
Phase 1/2 Completed